NCT06785584
- Conditions
- ALK-positive Advanced NSCLC, ALK-positive Non-small Cell Lung Cancer (NSCLC), MPR, +1 more
- Locations
-
- Fujian Medical University Union Hospital Fuzhou, Fujian, China
Clinical trial condition
ALK-positive Advanced NSCLC
Explore clinical trials studying ALK-positive Advanced NSCLC. Study availability and eligibility vary by location and protocol.
4 public trials
0 recruiting studies
ALK-positive Advanced NSCLC trial results
NCT03535740
- Conditions
- ALK-positive Advanced NSCLC
- Locations
-
- University of California Irvine Health Chao Family Comprehensive Cancer Center Orange, California, United States
- The Oncology Institute of Hope and Innovation Whittier, California, United States
- USOR - Rocky Mountain Cancer Centers - Pueblo Pueblo, Colorado, United States
- Florida Hospital Medical Group Orlando, Florida, United States
NCT03410108
- Conditions
- ALK-positive Advanced NSCLC
- Locations
-
- Aichi Cancer Center Hospital Nagoya, Aichi-ken, Japan
- Nagoya University Hospital Nagoya, Aichi-ken, Japan
- Fujita Health University Hospital Toyoake, Aichi-ken, Japan
- National Cancer Center Hospital East Kashiwa, Chiba, Japan
Active, Not Recruiting
A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment
NCT07567352
- Conditions
- ALK-positive Advanced NSCLC, ALK-positive NSCLC, ALK-positive Non-small-cell Lung Cancer, +11 more
- Locations
-
- Pfizer New York, United States